Phase II Study of Lenalidomide Maintenance in Patients With High Risk AML in Remission
Phase of Trial: Phase II
Latest Information Update: 30 Sep 2019
Price : $35 *
At a glance
- Drugs Lenalidomide (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 23 May 2019 Planned End Date changed from 1 Nov 2022 to 1 Nov 2023.
- 18 Dec 2018 Planned End Date changed from 1 Nov 2023 to 1 Nov 2022.
- 04 Dec 2018 Results assessing safety and tolerability of lenalidomide presented at the 60th Annual Meeting and Exposition of the American Society of Hematology